Randomized Study Comparing Lower Dose MR-Guided Radiation Therapy to Uniform Dose Treatment in Men With Prostate Cancer Using MR-Linac

What this Trial Is About

Researchers are evaluating whether giving a lower de-escalated dose of radiation therapy to specific parts of the prostate can reduce side effects compared to giving the same uniform dose of radiation therapy to the entire prostate. This randomized Phase 2 trial focuses on men with prostate adenocarcinoma, aiming to improve treatment tolerability by adjusting radiation doses guided by magnetic resonance imaging MRI. Participants receive MR-guided stereotactic body radiation therapy SBRT, which involves two radiation treatments. They are randomly assigned to either receive a uniform radiation dose to the whole prostate or a lower dose targeted to certain prostate areas. This study compares these two approaches to see if the lower dose reduces acute genitourinary toxicities within 12 weeks of starting treatment. During the trial, participants will undergo MRI scans to identify tumor areas and receive careful monitoring of side effects, particularly urinary symptoms. Researchers will assess acute genitourinary toxicities over 12 weeks after radiation begins using patient-reported outcomes and clinical evaluations. The trial requires men aged 18 or older and includes monitoring of organ function and overall health throughout the study period.

A Study of Lower Dose Radiation Therapy for People With Prostate Cancer